A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors

Trial Details

NCT ID
NCT07169994
Phase
PHASE1 / PHASE2
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • YL202 for injection; Toripalimab injection
  • YL202 for injection; Furmonertinib Mesilate Tablets
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Meizhou, Guangdong, China|24.28859,116.11768
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)
  • Able and willing to comply with protocol visits and procedures
  • Aged between 18 to 75 years
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →